Lupin Launches Generic Safyral Tablets In The Us
Pharma major Lupin has announced the launch of its Tydemy Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3 mg/0.03 mg/0.451 mg and Levomefolate Calcium, 0.451 mg) having received an approval from the USFDA earlier. The drug is the generic equivalent of Bayer HealthCare Pharmaceuticals Inc.’s Safyral tablets, which are indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception. It had annual sales of approximately $22-mn in the US.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
2026-07-14
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
NHU and Sinopec Advance Liquid Methionine Project
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
Recommend Reading
-
Glenmark Recalls Over 110000 Bottles of BP and COPD Drugs in US Due to Safety Concerns
-
Novo Nordisk Reports Theft of Six Drug Batches in India Authorities Warn of Severe Patient Safety Risks
-
Glenmark’s $1 Billion Cancer Bet: Oncology Revolution Set to Ignite in FY28
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
What is Element Stibium? (Antimony Facts & Uses)
-
Givaudan to Build New Fragrance Compounding Facility in Pedro Escobedo, Mexico
-
HAMR Plans $520 Million Methanol SAF Facility 125 Million Liters Output to Cut Airline Emissions
-
“Falling Revenue, Soaring Profits”: Is AkzoNobel’s Financial Alchemy Real Muscle—or Just Smoke and Mirrors?
-
Premium Global Chemical Sourcing Requests (2 - 6 Feb, 2026)